Risk of kidney disease with atazanavir-containing products

Risk of kidney disease with atazanavir-containing products Reactions 1664, p3 - 12 Aug 2017 Risk of kidney disease with atazanavir-containing products The risk of chronic kidney disease (CKD) is now included in the product information for two atazanavir- containing medicines in Canada. In the July issue of Health Product InfoWatch, it was reported that this risk had been included in the Canadian Product Monographs (CPMs) for atazanavir/cobicistat (Evotaz) and atazanavir alone (Reyataz). Specifically, the ’Warnings and Precautions’ and ’Adverse Reactions’ sections of the CPMs for these products will include the following key messages for healthcare professionals: CKD has been reported in patients treated with atazanavir (± ritonavir). Some cases resulted in fatal outcomes or requiring haemodialysis. Evotaz and Reyataz should be used with caution, especially in patients with other risk factors for CKD. Health Canada. Evotaz (atazanavir and cobicistat) and Reyataz (atazanavir). Health Product InfoWatch : 7, Jul 2017. Available from: URL: https://www.canada.ca/ content/dam/hc-sc/documents/services/drugs-health-products/medeffect- canada/health-product-infowatch/health-product-infowatch-july-2017/hpiw- ivps_2017-07-eng.pdf 803263661 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Risk of kidney disease with atazanavir-containing products

Reactions Weekly , Volume 1664 (1) – Aug 12, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/risk-of-kidney-disease-with-atazanavir-containing-products-6yZUo0vWaW
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-34283-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1664, p3 - 12 Aug 2017 Risk of kidney disease with atazanavir-containing products The risk of chronic kidney disease (CKD) is now included in the product information for two atazanavir- containing medicines in Canada. In the July issue of Health Product InfoWatch, it was reported that this risk had been included in the Canadian Product Monographs (CPMs) for atazanavir/cobicistat (Evotaz) and atazanavir alone (Reyataz). Specifically, the ’Warnings and Precautions’ and ’Adverse Reactions’ sections of the CPMs for these products will include the following key messages for healthcare professionals: CKD has been reported in patients treated with atazanavir (± ritonavir). Some cases resulted in fatal outcomes or requiring haemodialysis. Evotaz and Reyataz should be used with caution, especially in patients with other risk factors for CKD. Health Canada. Evotaz (atazanavir and cobicistat) and Reyataz (atazanavir). Health Product InfoWatch : 7, Jul 2017. Available from: URL: https://www.canada.ca/ content/dam/hc-sc/documents/services/drugs-health-products/medeffect- canada/health-product-infowatch/health-product-infowatch-july-2017/hpiw- ivps_2017-07-eng.pdf 803263661 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664

Journal

Reactions WeeklySpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off